Piper Sandler lowers Docusign stock price target due to billings miss

Piper Sandler lowered its price target on Docusign to $85 from $90, maintaining a Neutral rating, after the company reported billings below consensus due to fewer early renewals. This adjustment aligns with similar moves by BofA Securities, JPMorgan, and Morgan Stanley, all citing concerns over billings growth, sales force productivity, and macroeconomic uncertainties despite a Q1 revenue beat of $764 million. While Docusign sees traction in its IAM platform and maintains a 101% Net Revenue Retention rate, analysts remain cautious, reducing FY26 billings growth expectations and adopting a "wait-and-see" approach.

Analysis

Docusign Inc. (NASDAQ: DOCU) reported first-quarter total revenue of $764 million, a 7.6% year-over-year increase that slightly surpassed consensus expectations; however, the company's billings of $738 million fell short of its $746 million midpoint guidance, primarily due to lower-than-expected early renewals and changes in its go-to-market strategy. This billings miss has led to a cautious stance from analysts, with Piper Sandler lowering its price target to $85 from $90 while maintaining a Neutral rating, citing the billings shortfall and reduced fiscal year 2026 billings growth expectations despite favorable foreign exchange conditions. Similar adjustments were made by BofA Securities (price target lowered to $85, Neutral), JPMorgan (price target lowered to $77, Neutral), and Morgan Stanley (price target lowered to $86), with the latter also referencing sales force productivity issues and leadership turnover. Despite these challenges, Docusign demonstrated positive momentum with its Identity and Access Management (IAM) platform, achieved a Net Revenue Retention (NRR) rate of 101%, and boasts an impressive gross profit margin of 79.25% according to InvestingPro data, which also suggests the stock may be trading below its Fair Value. Nevertheless, Docusign's management has adopted a conservative outlook for bookings and early renewals, revising its full-year billings guidance downward due to fewer early renewals and macroeconomic factors, reinforcing the 'wait-and-see' approach advocated by analysts like Piper Sandler and Evercore ISI (In Line rating, $90.00 price target).

Key Decisions for Investors

• Investors should closely monitor Docusign's subsequent billings reports and commentary on early renewal trends, as these are pivotal to alleviating current analyst concerns and justifying a more bullish outlook.
• Considering the consensus Neutral ratings and downward revisions to price targets from multiple analysts due to billings underperformance and sales execution concerns, a cautious or hold stance may be warranted until there is tangible evidence of a turnaround in billings growth and improved go-to-market execution.
• While the reported strong gross profit margin and potential undervaluation indicated by InvestingPro data are noteworthy, these factors should be carefully weighed against the risks posed by reduced billings guidance, ongoing macroeconomic uncertainties, and internal challenges such as sales productivity and leadership transitions.